相关实验视频

Updated: Sep 18, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

基于免疫检查点抑制剂的疗法作为高级非小细胞肺癌的第一线治疗:有效性,挑战和未来前景

Xingxiang Pu¹, Yu Zhou², Jingyi Wang³

¹Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China.

Thoracic cancer

|June 24, 2025

概括

选择高级非小细胞肺癌 (NSCLC) 的一线治疗包括PD-L1测试和基因组分析. 优化免疫检查点抑制剂 (ICI) 组合是关键,但生存率的增长正在稳定,需要新的生物标志物和疗法.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
基因组学就是基因组学.

背景情况:

对于晚期非小细胞肺癌 (NSCLC) 的第一线治疗选择是非常重要的,因为疾病的进展很快.
治疗决策取决于组织学,驱动突变的基因组分析和PD-L1表达.
目前的指导方针强调在开始全身治疗之前对PD-L1进行评估.

研究的目的:

审查当前用于选择先进NSCLC的第一线系统性治疗的策略.
讨论免疫检查点抑制剂 (ICI) 和组合疗法的作用.
突出挑战和优化NSCLC治疗的未来方向.

主要方法:

对高级NSCLC的当前指导方针和临床实践的审查.
分析PD-L1表达和基因组分析的作用.
检查ICI单疗法与组合策略 (化疗或其他ICI).

主要成果:

单剂ICI是基本的,但与化疗或其他ICI相结合显示出更好的生存率.
有限的对比比较使最佳选择的选择变得复杂.
治疗决策受到实用因素的影响,例如药物的可用性和成本.

结论:

尽管ICI取得了进展,但晚期NSCLC的整体存活率似乎停滞不前.
需要进一步的研究来开发新的疗法和优化ICI组合.
生物标志物发现和协作努力对于改善患者选择和生存结果至关重要.

关键词:

在NSCLCLC中,我们可以看到.在PD-L1中.一线治疗的第一线治疗.免疫检查点抑制剂免疫检查点抑制剂

更多相关视频

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.